Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials.

Gadalla R, Noamani B, MacLeod BL, Dickson RJ, Guo M, Xu W, Lukhele S, Elsaesser HJ, Razak ARA, Hirano N, McGaha TL, Wang B, Butler M, Guidos CJ, Ohashi PS, Siu LL, Brooks DG.

Front Oncol. 2019 May 17;9:415. doi: 10.3389/fonc.2019.00415. eCollection 2019.

2.

TEMPORARY REMOVAL: Type I interferon signaling, regulation and gene stimulation in chronic virus infection.

Lukhele S, Boukhaled GM, Brooks DG.

Semin Immunol. 2019 May 30:101277. doi: 10.1016/j.smim.2019.05.001. [Epub ahead of print] No abstract available.

PMID:
31155227
3.

Correction: CRACR2A-Mediated TCR Signaling Promotes Local Effector Th1 and Th17 Responses.

Woo JS, Srikanth S, Kim KD, Elsaesser H, Lu J, Pellegrini M, Brooks DG, Sun Z, Gwack Y.

J Immunol. 2019 Jul 1;203(1):293. doi: 10.4049/jimmunol.1900492. Epub 2019 May 24. No abstract available.

PMID:
31127031
4.

CCR4 expression on host T cells is a driver for alloreactive responses and lung rejection.

Palchevskiy V, Xue YY, Kern R, Weigt SS, Gregson AL, Song SX, Fishbein MC, Hogaboam CM, Sayah DM, Lynch JP 3rd, Keane MP, Brooks DG, Belperio JA.

JCI Insight. 2019 May 14;5. pii: 121782. doi: 10.1172/jci.insight.121782.

5.

Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10.

Rojas OL, Pröbstel AK, Porfilio EA, Wang AA, Charabati M, Sun T, Lee DSW, Galicia G, Ramaglia V, Ward LA, Leung LYT, Najafi G, Khaleghi K, Garcillán B, Li A, Besla R, Naouar I, Cao EY, Chiaranunt P, Burrows K, Robinson HG, Allanach JR, Yam J, Luck H, Campbell DJ, Allman D, Brooks DG, Tomura M, Baumann R, Zamvil SS, Bar-Or A, Horwitz MS, Winer DA, Mortha A, Mackay F, Prat A, Osborne LC, Robbins C, Baranzini SE, Gommerman JL.

Cell. 2019 Apr 4;177(2):492-493. doi: 10.1016/j.cell.2019.03.037. No abstract available.

PMID:
30951673
6.

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL.

J Immunother Cancer. 2019 Mar 13;7(1):72. doi: 10.1186/s40425-019-0541-0.

7.

Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10.

Rojas OL, Pröbstel AK, Porfilio EA, Wang AA, Charabati M, Sun T, Lee DSW, Galicia G, Ramaglia V, Ward LA, Leung LYT, Najafi G, Khaleghi K, Garcillán B, Li A, Besla R, Naouar I, Cao EY, Chiaranunt P, Burrows K, Robinson HG, Allanach JR, Yam J, Luck H, Campbell DJ, Allman D, Brooks DG, Tomura M, Baumann R, Zamvil SS, Bar-Or A, Horwitz MS, Winer DA, Mortha A, Mackay F, Prat A, Osborne LC, Robbins C, Baranzini SE, Gommerman JL.

Cell. 2019 Jan 24;176(3):610-624.e18. doi: 10.1016/j.cell.2018.11.035. Epub 2019 Jan 3. Erratum in: Cell. 2019 Apr 4;177(2):492-493.

PMID:
30612739
8.

CD8+ T Cell Priming in Established Chronic Viral Infection Preferentially Directs Differentiation of Memory-like Cells for Sustained Immunity.

Snell LM, MacLeod BL, Law JC, Osokine I, Elsaesser HJ, Hezaveh K, Dickson RJ, Gavin MA, Guidos CJ, McGaha TL, Brooks DG.

Immunity. 2018 Oct 16;49(4):678-694.e5. doi: 10.1016/j.immuni.2018.08.002. Epub 2018 Oct 9.

PMID:
30314757
9.

CRACR2A-Mediated TCR Signaling Promotes Local Effector Th1 and Th17 Responses.

Woo JS, Srikanth S, Kim KD, Elsaesser H, Lu J, Pellegrini M, Brooks DG, Sun Z, Gwack Y.

J Immunol. 2018 Aug 15;201(4):1174-1185. doi: 10.4049/jimmunol.1800659. Epub 2018 Jul 9. Erratum in: J Immunol. 2019 Jul 1;203(1):293.

10.

Diagnostic accuracy of a prototype rapid chlamydia and gonorrhoea recombinase polymerase amplification assay: a multicentre cross-sectional preclinical evaluation.

Harding-Esch EM, Fuller SS, Chow SC, Nori AV, Harrison MA, Parker M, Piepenburg O, Forrest MS, Brooks DG, Patel R, Hay PE, Fearnley N, Pond MJ, Dunbar JK, Butcher PD, Planche T, Lowndes CM, Sadiq ST.

Clin Microbiol Infect. 2019 Mar;25(3):380.e1-380.e7. doi: 10.1016/j.cmi.2018.06.003. Epub 2018 Jun 12.

11.

A CD103+ Conventional Dendritic Cell Surveillance System Prevents Development of Overt Heart Failure during Subclinical Viral Myocarditis.

Clemente-Casares X, Hosseinzadeh S, Barbu I, Dick SA, Macklin JA, Wang Y, Momen A, Kantores C, Aronoff L, Farno M, Lucas TM, Avery J, Zarrin-Khat D, Elsaesser HJ, Razani B, Lavine KJ, Husain M, Brooks DG, Robbins CS, Cybulsky M, Epelman S.

Immunity. 2017 Nov 21;47(5):974-989.e8. doi: 10.1016/j.immuni.2017.10.011.

12.

Purging Exhausted Virus-Specific CD8 T Cell Phenotypes by Somatic Cell Reprogramming.

Chan J, Kim PY, Kranz E, Nagaoka Y, Lee Y, Wen J, Elsaesser HJ, Qin M, Brooks DG, Ringpis GE, Chen ISY, Kamata M.

AIDS Res Hum Retroviruses. 2017 Nov;33(S1):S59-S69. doi: 10.1089/aid.2017.0161.

13.

Type I Interferon in Chronic Virus Infection and Cancer.

Snell LM, McGaha TL, Brooks DG.

Trends Immunol. 2017 Aug;38(8):542-557. doi: 10.1016/j.it.2017.05.005. Epub 2017 May 31. Review.

PMID:
28579323
14.

Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.

Zhen A, Rezek V, Youn C, Lam B, Chang N, Rick J, Carrillo M, Martin H, Kasparian S, Syed P, Rice N, Brooks DG, Kitchen SG.

J Clin Invest. 2017 Jan 3;127(1):260-268. doi: 10.1172/JCI89488. Epub 2016 Dec 12.

15.

Overcoming CD4 Th1 Cell Fate Restrictions to Sustain Antiviral CD8 T Cells and Control Persistent Virus Infection.

Snell LM, Osokine I, Yamada DH, De la Fuente JR, Elsaesser HJ, Brooks DG.

Cell Rep. 2016 Sep 20;16(12):3286-3296. doi: 10.1016/j.celrep.2016.08.065.

16.

Type I and Type II Interferon Coordinately Regulate Suppressive Dendritic Cell Fate and Function during Viral Persistence.

Cunningham CR, Champhekar A, Tullius MV, Dillon BJ, Zhen A, de la Fuente JR, Herskovitz J, Elsaesser H, Snell LM, Wilson EB, de la Torre JC, Kitchen SG, Horwitz MA, Bensinger SJ, Smale ST, Brooks DG.

PLoS Pathog. 2016 Jan 25;12(1):e1005356. doi: 10.1371/journal.ppat.1005356. eCollection 2016 Jan.

17.

Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling.

York AG, Williams KJ, Argus JP, Zhou QD, Brar G, Vergnes L, Gray EE, Zhen A, Wu NC, Yamada DH, Cunningham CR, Tarling EJ, Wilks MQ, Casero D, Gray DH, Yu AK, Wang ES, Brooks DG, Sun R, Kitchen SG, Wu TT, Reue K, Stetson DB, Bensinger SJ.

Cell. 2015 Dec 17;163(7):1716-29. doi: 10.1016/j.cell.2015.11.045. Epub 2015 Dec 10.

18.

LKB1 inhibition of NF-κB in B cells prevents T follicular helper cell differentiation and germinal center formation.

Walsh NC, Waters LR, Fowler JA, Lin M, Cunningham CR, Brooks DG, Rehg JE, Morse HC 3rd, Teitell MA.

EMBO Rep. 2015 Jun;16(6):753-68. doi: 10.15252/embr.201439505. Epub 2015 Apr 26.

19.

New insights into type I interferon and the immunopathogenesis of persistent viral infections.

Snell LM, Brooks DG.

Curr Opin Immunol. 2015 Jun;34:91-8. doi: 10.1016/j.coi.2015.03.002. Epub 2015 Mar 13. Review.

20.

Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection.

Yamada DH, Elsaesser H, Lux A, Timmerman JM, Morrison SL, de la Torre JC, Nimmerjahn F, Brooks DG.

Immunity. 2015 Feb 17;42(2):379-390. doi: 10.1016/j.immuni.2015.01.005. Epub 2015 Feb 10.

21.

Rapid detection of Mycobacterium tuberculosis by recombinase polymerase amplification.

Boyle DS, McNerney R, Teng Low H, Leader BT, Pérez-Osorio AC, Meyer JC, O'Sullivan DM, Brooks DG, Piepenburg O, Forrest MS.

PLoS One. 2014 Aug 13;9(8):e103091. doi: 10.1371/journal.pone.0103091. eCollection 2014.

22.

Decoding the complexity of type I interferon to treat persistent viral infections.

Wilson EB, Brooks DG.

Trends Microbiol. 2013 Dec;21(12):634-40. doi: 10.1016/j.tim.2013.10.003. Epub 2013 Nov 8. Review.

23.

Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses.

Gillespie EJ, Ho CL, Balaji K, Clemens DL, Deng G, Wang YE, Elsaesser HJ, Tamilselvam B, Gargi A, Dixon SD, France B, Chamberlain BT, Blanke SR, Cheng G, de la Torre JC, Brooks DG, Jung ME, Colicelli J, Damoiseaux R, Bradley KA.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):E4904-12. doi: 10.1073/pnas.1302334110. Epub 2013 Nov 4.

24.

Discovery of novel drugs for promising targets.

Martell RE, Brooks DG, Wang Y, Wilcoxen K.

Clin Ther. 2013 Sep;35(9):1271-81. doi: 10.1016/j.clinthera.2013.08.005. Review.

PMID:
24054704
25.

Interfering with type I interferon: a novel approach to purge persistent viral infection.

Wilson EB, Brooks DG.

Cell Cycle. 2013 Sep 15;12(18):2919-20. doi: 10.4161/cc.26175. Epub 2013 Aug 23. No abstract available.

26.

Networking at the level of host immunity: immune cell interactions during persistent viral infections.

Ng CT, Snell LM, Brooks DG, Oldstone MB.

Cell Host Microbe. 2013 Jun 12;13(6):652-64. doi: 10.1016/j.chom.2013.05.014. Review.

27.

Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, Aronow BJ, Karp CL, Brooks DG.

Science. 2013 Apr 12;340(6129):202-7. doi: 10.1126/science.1235208.

28.

Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity.

Kidani Y, Elsaesser H, Hock MB, Vergnes L, Williams KJ, Argus JP, Marbois BN, Komisopoulou E, Wilson EB, Osborne TF, Graeber TG, Reue K, Brooks DG, Bensinger SJ.

Nat Immunol. 2013 May;14(5):489-99. doi: 10.1038/ni.2570. Epub 2013 Apr 7.

29.

Inflammation makes T cells sensitive.

Wilson EB, Brooks DG.

Immunity. 2013 Jan 24;38(1):5-7. doi: 10.1016/j.immuni.2013.01.001.

30.

Emergence of distinct multiarmed immunoregulatory antigen-presenting cells during persistent viral infection.

Wilson EB, Kidani Y, Elsaesser H, Barnard J, Raff L, Karp CL, Bensinger S, Brooks DG.

Cell Host Microbe. 2012 May 17;11(5):481-91. doi: 10.1016/j.chom.2012.03.009.

31.

Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing.

Canestaro WJ, Brooks DG, Chaplin D, Choudhry NK, Lawler E, Martell L, Brennan T, Wassman ER.

J Pers Med. 2012 Oct 17;2(4):158-74. doi: 10.3390/jpm2040158.

32.

Caveolin-1 orchestrates TCR synaptic polarity, signal specificity, and function in CD8 T cells.

Tomassian T, Humphries LA, Liu SD, Silva O, Brooks DG, Miceli MC.

J Immunol. 2011 Sep 15;187(6):2993-3002. doi: 10.4049/jimmunol.1101447. Epub 2011 Aug 17.

33.

Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells.

Fahey LM, Wilson EB, Elsaesser H, Fistonich CD, McGavern DB, Brooks DG.

J Exp Med. 2011 May 9;208(5):987-99. doi: 10.1084/jem.20101773. Epub 2011 May 2.

34.

Translating insights from persistent LCMV infection into anti-HIV immunity.

Wilson EB, Brooks DG.

Immunol Res. 2010 Dec;48(1-3):3-13. doi: 10.1007/s12026-010-8162-1. Review.

35.

The role of IL-10 in regulating immunity to persistent viral infections.

Wilson EB, Brooks DG.

Curr Top Microbiol Immunol. 2011;350:39-65. doi: 10.1007/82_2010_96. Review.

36.

Opposing positive and negative regulation of T cell activity during viral persistence.

Fahey LM, Brooks DG.

Curr Opin Immunol. 2010 Jun;22(3):348-54. doi: 10.1016/j.coi.2010.03.004. Epub 2010 Apr 8. Review.

37.

IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection.

Brooks DG, Walsh KB, Elsaesser H, Oldstone MB.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3018-23. doi: 10.1073/pnas.0914500107. Epub 2010 Jan 26.

38.

Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways.

Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE, Winton DJ, Arends MJ.

Int J Exp Pathol. 2009 Oct;90(5):558-74. doi: 10.1111/j.1365-2613.2009.00667.x.

39.

Expanding CEP290 mutational spectrum in ciliopathies.

Travaglini L, Brancati F, Attie-Bitach T, Audollent S, Bertini E, Kaplan J, Perrault I, Iannicelli M, Mancuso B, Rigoli L, Rozet JM, Swistun D, Tolentino J, Dallapiccola B, Gleeson JG, Valente EM; International JSRD Study Group, Zankl A, Leventer R, Grattan-Smith P, Janecke A, D'Hooghe M, Sznajer Y, Van Coster R, Demerleir L, Dias K, Moco C, Moreira A, Kim CA, Maegawa G, Petkovic D, Abdel-Salam GM, Abdel-Aleem A, Zaki MS, Marti I, Quijano-Roy S, Sigaudy S, de Lonlay P, Romano S, Touraine R, Koenig M, Lagier-Tourenne C, Messer J, Collignon P, Wolf N, Philippi H, Kitsiou Tzeli S, Halldorsson S, Johannsdottir J, Ludvigsson P, Phadke SR, Udani V, Stuart B, Magee A, Lev D, Michelson M, Ben-Zeev B, Fischetto R, Benedicenti F, Stanzial F, Borgatti R, Accorsi P, Battaglia S, Fazzi E, Giordano L, Pinelli L, Boccone L, Bigoni S, Ferlini A, Donati MA, Caridi G, Divizia MT, Faravelli F, Ghiggeri G, Pessagno A, Briguglio M, Briuglia S, Salpietro CD, Tortorella G, Adami A, Castorina P, Lalatta F, Marra G, Riva D, Scelsa B, Spaccini L, Uziel G, Del Giudice E, Laverda AM, Ludwig K, Permunian A, Suppiej A, Signorini S, Uggetti C, Battini R, Di Giacomo M, Cilio MR, Di Sabato ML, Leuzzi V, Parisi P, Pollazzon M, Silengo M, De Vescovi R, Greco D, Romano C, Cazzagon M, Simonati A, Al-Tawari AA, Bastaki L, Mégarbané A, Sabolic Avramovska V, de Jong MM, Stromme P, Koul R, Rajab A, Azam M, Barbot C, Martorell Sampol L, Rodriguez B, Pascual-Castroviejo I, Teber S, Anlar B, Comu S, Karaca E, Kayserili H, Yüksel A, Akcakus M, Al Gazali L, Sztriha L, Nicholl D, Woods CG, Bennett C, Hurst J, Sheridan E, Barnicoat A, Hennekam R, Lees M, Blair E, Bernes S, Sanchez H, Clark AE, DeMarco E, Donahue C, Sherr E, Hahn J, Sanger TD, Gallager TE, Dobyns WB, Daugherty C, Krishnamoorthy KS, Sarco D, Walsh CA, McKanna T, Milisa J, Chung WK, De Vivo DC, Raynes H, Schubert R, Seward A, Brooks DG, Goldstein A, Caldwell J, Finsecke E, Maria BL, Holden K, Cruse RP, Swoboda KJ, Viskochil D.

Am J Med Genet A. 2009 Oct;149A(10):2173-80. doi: 10.1002/ajmg.a.33025.

40.

Suppressing the suppressor.

Brooks DG.

Blood. 2009 Jul 9;114(2):233. doi: 10.1182/blood-2009-04-218073. No abstract available.

41.

Therapeutic memory T cells require costimulation for effective clearance of a persistent viral infection.

Garidou L, Heydari S, Truong P, Brooks DG, McGavern DB.

J Virol. 2009 Sep;83(17):8905-15. doi: 10.1128/JVI.00027-09. Epub 2009 Jun 24.

42.

IL-21 is required to control chronic viral infection.

Elsaesser H, Sauer K, Brooks DG.

Science. 2009 Jun 19;324(5934):1569-72. doi: 10.1126/science.1174182. Epub 2009 May 7. Erratum in: Science. 2009 Aug 21;325(5943):946.

43.

IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection.

Brooks DG, Ha SJ, Elsaesser H, Sharpe AH, Freeman GJ, Oldstone MB.

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20428-33. doi: 10.1073/pnas.0811139106. Epub 2008 Dec 15.

44.

Cardiolipin provides an essential activating platform for caspase-8 on mitochondria.

Gonzalvez F, Schug ZT, Houtkooper RH, MacKenzie ED, Brooks DG, Wanders RJ, Petit PX, Vaz FM, Gottlieb E.

J Cell Biol. 2008 Nov 17;183(4):681-96. doi: 10.1083/jcb.200803129. Epub 2008 Nov 10.

45.

IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection.

Brooks DG, Lee AM, Elsaesser H, McGavern DB, Oldstone MB.

J Exp Med. 2008 Mar 17;205(3):533-41. doi: 10.1084/jem.20071948. Epub 2008 Mar 10.

46.

Stem cell gene expression changes induced specifically by mutated K-ras.

Luo F, Hamoudi R, Brooks DG, Patek CE, Arends MJ.

Gene Expr. 2007;14(2):101-15.

47.

Anabolic steroids causing growth of benign tumors: androgen receptor in angiolipomas.

Syed SP, Brooks DG, Haupt HM, Bellucci K, Martin AM, Podolski V, Brooks JJ.

J Am Acad Dermatol. 2007 Nov;57(5):899-900. No abstract available.

PMID:
17939941
48.

Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice.

Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE, Winton DJ, Arends MJ.

Oncogene. 2007 Jun 28;26(30):4415-27. Epub 2007 Feb 5.

PMID:
17297472
49.

Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1.

Stewart DR, Corless CL, Rubin BP, Heinrich MC, Messiaen LM, Kessler LJ, Zhang PJ, Brooks DG.

J Med Genet. 2007 Jan;44(1):e61.

50.

Interleukin-10 determines viral clearance or persistence in vivo.

Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB.

Nat Med. 2006 Nov;12(11):1301-9. Epub 2006 Oct 15.

Supplemental Content

Loading ...
Support Center